share_log

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Benzinga Real-time News ·  Sep 22, 2022 08:37

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE:ATR) in 2019, as part of the company's strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

This press...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment